Roggwil, October 25, 2021 – Based on patient feedback, we can report that the tinniwell with its patented heat therapy has a very good effect on migraine patients. 30 – 60 minutes before the aura occurs in affected individuals, they have treated their tinnitus with the tinniwell. Patients report that the aura in these cases is very mild or has not occurred at all. Since about 10% of the population suffers from migraines, this represents a significant potential expansion of the patient base for the tinniwell.

The management of Resaphene would like to conduct a clinical user observation regarding this possible expansion of treatment options. Currently, the market is being surveyed for potential cooperation partners.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG


Ms. Anke Rauterkus (Chief Executive Officer)

Bahnhofplatz 5

9322 Egnach


Switzerland

T. +41 714500668


a.rauterkus@resaphene.ch